LQDA
Liquidia Corporation
$60.98
-0.99
(-1.60%)
Mkt Cap
5.42B
Volume
957,199
52W Range
11.85-62.3
Sector
Healthcare
Beta
0.42
EPS (TTM)
0.24
P/E Ratio
255.04
Revenue (TTM)
288.06M
Rev Growth (5Y)
+192.5%
EPS Growth (5Y)
N/A
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.32M | 14.00M | 17.49M | 15.94M | 12.85M | 739,628 | 8.07M | 2.71M | 7.26M | 13.22M |
| Net Income | (68.92M) | (130.39M) | (78.50M) | (41.02M) | (34.58M) | (59.76M) | (47.58M) | (53.14M) | (29.15M) | (15.93M) |
| EPS | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | -3.40 | -1.86 |
| Free Cash Flow | (40.02M) | (98.37M) | (42.85M) | (29.18M) | (34.14M) | (54.90M) | (50.13M) | (32.70M) | (26.83M) | (16.83M) |
| FCF / Share | -0.47 | -1.25 | -0.66 | -0.48 | -0.69 | -1.62 | -2.71 | -4.57 | -3.13 | -1.96 |
| Operating CF | (35.69M) | (93.42M) | (41.56M) | (28.59M) | (34.03M) | (54.14M) | (48.28M) | (31.83M) | (24.29M) | (13.95M) |
| Total Assets | 327.93M | 230.31M | 118.33M | 129.20M | 93.73M | 99.53M | 68.84M | 49.42M | 14.84M | 8.49M |
| Total Debt | 197.93M | 122.39M | 49.54M | 24.46M | 16.08M | 17.14M | 24.42M | 12.77M | 22.15M | 8.68M |
| Cash & Equiv | 190.68M | 176.48M | 83.68M | 93.28M | 57.49M | 65.32M | 55.80M | 39.53M | 3.42M | 1.44M |
| Book Value | 44.75M | 77.28M | 47.29M | 90.42M | 65.27M | 71.09M | 34.95M | 18.69M | (33.69M) | (18.25M) |
| Return on Equity | -1.54 | -1.69 | -1.66 | -0.45 | -0.53 | -0.84 | -1.36 | -2.84 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 132.87M | 92.02M | 54.34M | 8.84M | 3.12M | 2.92M | 4.45M | 3.66M | 2.97M | 4.53M | 3.68M | 4.79M |
| Net Income | 52.86M | 14.55M | (3.53M) | (41.58M) | (38.37M) | (38.37M) | (23.16M) | (27.94M) | (40.93M) | (27.45M) | (15.79M) | (23.52M) |
| EPS | 0.60 | 0.17 | -0.04 | -0.49 | -0.45 | -0.45 | -0.30 | -0.37 | -0.54 | -0.42 | -0.24 | -0.36 |
| Free Cash Flow | 50.16M | 42.21M | (10.68M) | (40.54M) | (31.01M) | (25.60M) | (26.83M) | (23.95M) | (25.49M) | (16.19M) | (22.04M) | (5.81M) |
| FCF / Share | 0.57 | 0.48 | -0.12 | -0.47 | -0.36 | -0.30 | -0.34 | -0.31 | -0.34 | -0.25 | -0.34 | -0.09 |
| Operating CF | 52.99M | 44.24M | (9.77M) | (39.48M) | (30.68M) | (20.81M) | (25.08M) | (22.66M) | (24.87M) | (15.98M) | (11.56M) | (5.56M) |
| Total Assets | 401.53M | 327.93M | 275.98M | 257.41M | 227.43M | 230.31M | 252.89M | 177.36M | 197.12M | 118.33M | 111.64M | 121.60M |
| Total Debt | 184.82M | 197.93M | 199.18M | 200.38M | 147.66M | 122.39M | 2.69M | 2.95M | 3.23M | 49.54M | 3.77M | 4.02M |
| Cash & Equiv | 222.79M | 190.68M | 157.50M | 173.42M | 169.76M | 176.48M | 204.37M | 133.09M | 157.86M | 83.68M | 76.22M | 88.20M |
| Book Value | 108.58M | 44.75M | 22.05M | 15.19M | 49.71M | 77.28M | 110.52M | 62.72M | 86.26M | 47.29M | 48.01M | 60.66M |
| Return on Equity | 0.49 | 0.33 | -0.16 | -2.74 | -0.77 | -0.50 | -0.21 | -0.45 | -0.47 | -0.58 | -0.33 | -0.39 |
LQDA News
4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG
Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
Best Momentum Stocks to Buy for May 13th
New Strong Buy Stocks for May 13th
These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Liquidia Q1 Earnings Call Highlights